Associated tags: CO, Science, Education, University, Apsis, Internet, Student, Mobile, Wireless, Networks
Locations: NORTH CAROLINA, TEXAS, UNITED STATES, NORTH AMERICA, FAYETTEVILLE, ALABAMA, LOUISIANA, SHREVEPORT, US, SAN FRANCISCO, CALIFORNIA, EUREKA, , KANSAS, TENNESSEE
I&I,
TARC,
Atopic dermatitis,
Disease,
Half-life,
Patient,
SAN,
Heel,
IND,
Respiratory disease,
Asthma,
SQ,
Clinical trial,
Therapy,
Safety,
Pharmacokinetics,
Engineering,
Pharmaceutical industry SAN FRANCISCO and WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), COPD, asthma and other inflammatory and immunology (I&I) indications, today announced that it has initiated dosing of healthy volunteers in its first clinical trial for APG808, a novel subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-4Rα, which is being developed as a treatment for people living with moderate-to-severe COPD, asthma and other I&I diseases.
Key Points:
- COPD is a progressive respiratory disease that is estimated to affect approximately 10 percent of the global population 40 years of age and older.
- Despite recent advancements in COPD treatment, a significant number of people continue to suffer and die from the disease.
- The APG808 Phase 1 trial is designed as a double-blind, placebo-controlled, first-in-human, single-ascending dose trial in healthy volunteers.
- Importantly, this points to potentially less frequent dosing for patients with COPD, which could significantly improve quality of life.”
Attention,
SAN,
Apsis,
Lexington Avenue,
Jefferies Group,
Prospectus,
Suite,
Telephone,
Atopic dermatitis,
Asthma,
Sale,
Exercise,
Montgomery Street,
Chronic obstructive pulmonary disease,
Therapy,
Madison Avenue,
BofA Securities,
Security (finance),
Goldman Sachs,
Jefferies The aggregate gross proceeds to Apogee from the offering are expected to be approximately $420.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee, excluding any exercise of the underwriters’ option to purchase additional shares.
Key Points:
- The aggregate gross proceeds to Apogee from the offering are expected to be approximately $420.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee, excluding any exercise of the underwriters’ option to purchase additional shares.
- The offering is expected to close on March 12, 2024, subject to the satisfaction of customary closing conditions.
- In addition, Apogee has granted the underwriters a 30-day option to purchase up to an additional 1,016,128 shares of common stock at the public offering price, less underwriting discounts and commissions.
- Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD Cowen and Stifel are acting as joint book-running managers for the offering.
Attention,
SAN,
Apsis,
Lexington Avenue,
Jefferies Group,
Suite,
Telephone,
Atopic dermatitis,
Asthma,
Sale,
Montgomery Street,
Chronic obstructive pulmonary disease,
Therapy,
Madison Avenue,
BofA Securities,
Security (finance),
Goldman Sachs,
Jefferies In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock at the public offering price, less underwriting discounts and commissions.
Key Points:
- In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock at the public offering price, less underwriting discounts and commissions.
- The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
- Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD Cowen, and Stifel are acting as joint book-running managers for the proposed offering.
- This offering will be made only by means of a written prospectus.
SQ,
PD,
Injection,
I&I,
Research,
OX40L,
Inflammation,
Atopic dermatitis,
Growth,
Asthma,
TARC,
Chronic obstructive pulmonary disease,
IPO,
Interim,
Safety,
Therapy,
Pharmacokinetics,
Patient,
Clinical trial,
Half-life,
G&A,
Pharmaceutical industry SAN FRANCISCO and WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications, today reported pipeline highlights and fourth quarter and full year 2023 financial results.
Key Points:
- “2023 was a momentous year for Apogee with the completion of a successful IPO, initiation of our first clinical program of APG777 in healthy volunteers and the nomination of our second pipeline candidate, APG808,” said Michael Henderson, M.D., Chief Executive Officer of Apogee.
- Cash Position: Cash, cash equivalents and marketable securities were $395.5 million as of December 31, 2023, compared to $151.9 million as of December 31, 2022.
- Based on current operating plans, Apogee expects its existing cash, cash equivalents and marketable securities will enable the company to fund its operating expenses into 4Q 2026.
- Net loss increased primarily as a result of higher R&D and G&A operating expenses as described above, partially offset by higher interest income.
Paragon,
Well,
SAD,
PD,
Injection,
I&I,
Waldman,
Headache,
Inflammation,
Quality of life,
Management,
Atopic dermatitis,
Asthma,
TARC,
AUC,
Volunteering,
Cmax,
Chronic obstructive pulmonary disease,
Outline of health sciences,
Safety,
Biomarker,
Therapy,
CQD,
Chronic pain,
Immunology,
IGA,
Webcast,
Sleep,
Patient,
MPH,
Half-life,
Serum,
Pharmaceutical industry Based on these data, the company plans to initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with moderate-to-severe AD in the first half of 2024 ahead of schedule.
Key Points:
- Based on these data, the company plans to initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with moderate-to-severe AD in the first half of 2024 ahead of schedule.
- At Apogee, we refuse to stop at good enough and are dedicated to advancing innovative solutions for patients.
- The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate safety and PK of APG777 in healthy volunteers.
- A live webcast of the call will be available on the Investor Relations page of Apogee’s website at https://investors.apogeetherapeutics.com/news-events/events .
(Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology (I&I) indications, today announced it will report interim results from the Phase 1 APG777 healthy volunteer trial on Tuesday, March 5, 2024.
Key Points:
- (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology (I&I) indications, today announced it will report interim results from the Phase 1 APG777 healthy volunteer trial on Tuesday, March 5, 2024.
- Following the announcement, the Company will host a conference call and webcast at 7:00am ET to discuss the results.
- To access the live and archived webcast, please visit the Investor Relations page of Apogee’s website at https://investors.apogeetherapeutics.com/news-events/events .
- The archived webcast will be available for a limited time on the Company’s website.
Retrieved on:
Wednesday, February 7, 2024
Technology,
Mobile,
Wireless,
Other Professional Services,
Consulting,
Other Education,
Professional Services,
Continuing,
University,
Other Technology,
Education,
Networks,
Internet,
Data Management,
Security,
Azure,
Knowledge,
Certification,
Cisco,
ISC2,
MSP,
CISSP,
Managed services,
Faculty,
Microsoft Certified Professional,
School,
MCP,
CEH,
Amazon Web Services,
CompTIA,
Microsoft,
Linux,
Microsoft Azure,
Information,
Certified Ethical Hacker,
Brocade,
Picart,
Student,
AWS,
Management Jacob Picart has joined Apogee, Inc. , in the role of vice president for Security Services .
Key Points:
- Jacob Picart has joined Apogee, Inc. , in the role of vice president for Security Services .
- A member of the Apogee executive leadership team, Picart is responsible for expanding the company’s comprehensive portfolio of information security services for colleges and universities.
- Committed to empowering and protecting Apogee customers, Picart also oversees Apogee’s network of virtual chief information security officers (vCISOs) and security partners.
- His knowledge and experience have accelerated our ability to deliver essential security services that complement our current managed network services and cloud services offerings,” said Scott Drossos, chief executive officer of Apogee.
Retrieved on:
Wednesday, February 7, 2024
TORONTO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Apogee Interactive announced today the acquisition of EnergyX Solutions, Inc. , an Ontario-based creator of artificial-intelligence-powered software for utilities.
Key Points:
- TORONTO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Apogee Interactive announced today the acquisition of EnergyX Solutions, Inc. , an Ontario-based creator of artificial-intelligence-powered software for utilities.
- Operating in the United States and Canada, EnergyX leverages data science to increase customer participation in energy efficiency programs.
- EnergyX's RetrofitAI technology enables utilities to perform cost-effective virtual building audits at scale across their entire service territory resulting in increased customer segmentation, targeting, and energy efficiency program uptake.
- “Joining the extended Apogee team is a great fit for EnergyX, as we specialize in customer journey software for utility customers, streamlining the identification of ideal targets for energy savings programs,” said Nishaant Sangaavi, President of EnergyX.
Retrieved on:
Thursday, January 4, 2024
Workforce,
Hospital,
MAJCOM,
University,
Sociology,
Air force,
The King's Daughters,
Education,
College,
Federation,
Apsis,
Mental health,
Professional,
Daughter,
Volunteering,
Anthropology,
DHS,
CHKD,
Management COLORADO SPRINGS, Colo., Jan. 4, 2024 /PRNewswire/ -- Apogee, a leading defense and security solutions provider, announced the promotion of Anitra Simmons to director of operations for its Mission Operations portfolio effective Nov. 1, 2023.
Key Points:
- COLORADO SPRINGS, Colo., Jan. 4, 2024 /PRNewswire/ -- Apogee, a leading defense and security solutions provider, announced the promotion of Anitra Simmons to director of operations for its Mission Operations portfolio effective Nov. 1, 2023.
- In this role Simmons will lead program implementation and support federal government business development for Apogee's Mission Operations portfolio which is focused on U.S. Department of Defense (DoD) and Department of Homeland Security (DHS) programs.
- The company's mission operations include 15 projects and 118 employees across Federal Agency Operations, Air Force (AF) Operations and Sustainment, and AF Major Commands (MAJCOM) Staff programs.
- "Anitra has continually dedicated herself to the mission of our customers and maintains the highest level of professionalism with our workforce and within our local communities.
Retrieved on:
Monday, November 13, 2023
European Academy of Management,
Safety,
SAN,
General counsel,
Research and development,
Therapy,
IND,
Initial public offering,
Exercise,
Clinical trial,
Administration,
Aulus Cornelius Cossus Arvina,
Patient,
TARC,
G&A,
Pharmacokinetics,
Atopic dermatitis,
Conference,
IPO,
Half-life,
R,
Growth,
Chronic obstructive pulmonary disease,
Congress,
Health,
I&I,
Asthma,
Inflammation,
Vaccine,
Pharmaceutical industry,
COPD,
Apsis,
Venereology,
Dermatology SAN FRANCISCO and WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today provided business updates and reported third quarter 2023 financial results.
Key Points:
- “I am proud of our team’s execution during the third quarter and 2023 overall.
- Research & Development (R&D) Expenses: R&D expenses for the third quarter of 2023 were $17.1 million, compared to $9.9 million for the third quarter of 2022.
- General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2023 were $7.2 million, compared to $0.6 million for the third quarter of 2022.
- Net Loss: Net loss for the third quarter of 2023 was $20.8 million, compared to the net loss for the third quarter of 2022 which was $19.7 million.
